<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0805014-A6FD-41C1-81BE-B94AE4139F25"><gtr:id>C0805014-A6FD-41C1-81BE-B94AE4139F25</gtr:id><gtr:name>Max Planck Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/31523941-725F-4111-9249-C2F87B89018C"><gtr:id>31523941-725F-4111-9249-C2F87B89018C</gtr:id><gtr:firstName>Ifedayo</gtr:firstName><gtr:surname>Adetifa</gtr:surname><gtr:orcidId>0000-0003-2556-9407</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190081968"><gtr:id>5E05EAB7-B6D2-40C9-990F-030349EA4C13</gtr:id><gtr:title>Double blind placebo-controlled randomized trial of isoniazid for reversion of positive IFNg ELISPOT in TB case contacts</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190081968</gtr:grantReference><gtr:abstractText>Tuberculosis is a very important cause of death and illness among Gambians. Many individuals are infected with the bacteria that cause Tuberculosis disease without knowing it. In some countries, such individuals are given Isoniazid to prevent them developing tuberculosis disease. However it may be too difficult to do this in The Gambia. It might be possible to give a vaccine if one is shown to help clear the infection. We have a plan to prove whether isoniazid works in certain people in The Gambia to clear the infection and to see whether we can pick up that it is working by doing a blood test.We will compare the action of this medicine and a placebo. Before the trial commences subjects will have a physical examination including a chest x-ray and blood tests to check the health status. Participants will then be allocated to one of these two groups. Vitamin B tablets will be given to prevent the most common side effect. The medication is given over a six month period. During this period, participants will monitored at home by fieldworkers and visit the site for collection of blood to test how the immune response is over a period of time and to check the health status.</gtr:abstractText><gtr:technicalSummary>Current efforts to control the spread of tuberculosis are failing. An increasingly large number of new generation vaccines are being produced and a plan for assessing their ability to prevent disease and treat infection needs to be developed. The MRC Labs in The Gambia is well positioned to conduct safety and immunogenicity studies and also to conduct trials of the therapeutic effect of these vaccines in preventing disease in case contacts who are infected. This study is part one of a three-step plan to develop a reliable early surrogate marker of the therapeutic efficacy of new TB vaccines.The three-step plan is as follows:Evaluate the ability of isoniazid, known to be effective in the treatment of MTB infection, to revert the antigen-specific IFNg-ELISPOT in ESAT 6 and/or CFP-10 positive contacts of TB patients.Compare the ability of different combinations of a TB vaccine and isoniazid to revert the ELISPOT in a 4-arm randomized trial using:1) isoniazid alone, 2) a TB vaccine alone, 3) a combination of isoniazid and TB vaccine, and 4) placebo Compare, in a randomized trial, the ability of TB vaccine or vaccine plus isoniazid versus isoniazid alone to prevent the development of secondary disease.For this first step we will test the following hypothesis:Those receiving isoniazid have a significantly higher reversion rate of MTB-specific responses as measured with IFNg-ELISPOT assays compared to those who receive a placebo</gtr:technicalSummary><gtr:fund><gtr:end>2009-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3391348</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Max Planck Society</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Max Planck Institute for Infection Biology</gtr:department><gtr:description>Biomarkers for TB in Africa</gtr:description><gtr:id>46F40B5F-E377-4A3D-9866-11C5F1858AFD</gtr:id><gtr:impact>Publications
1.Clin Vaccine Immunol. 2009 Aug;16(8):1203-12. Epub 2009 Jun 24
2.Tuberculosis (Edinb). 2009 Nov;89(6):398-404. Epub 2009 Aug 14
3.Eur J Immunol. 2009 Mar;39(3):723-9.
Multidisciplinaty collaboration
1.Immunology
2.Molecular biology
3.Mycobacteriology/Clinical Microbiology
4.Epidemiology</gtr:impact><gtr:outcomeId>Sx763jzZ7YT-1</gtr:outcomeId><gtr:piContribution>Our site takes the lead on work package 3 which is natural history studies of TB in low HIV settings. We have currently contributed the largest proportion of recruited study subjects.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical utility of IGRA for TB in high-burden vs.low-burden settings</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B4906C80-DD5C-41F3-928B-301396434568</gtr:id><gtr:impact>World Health Organization is about to release recommendations regarding the use of Interferon gamma release assays in high burden Tuberculosis sttings. From advance information given at the 2010 IUATLD meeting in Berlin, our data has contributed to plans by WHO to discourage the use of IGRAs in high burden TB settings.</gtr:impact><gtr:outcomeId>FcTCKzyV1rz</gtr:outcomeId><gtr:type>Citation in systematic reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DBA4E2EA-4D51-49EB-B424-B6C54587A7D8</gtr:id><gtr:title>Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>McFbC8DiGSZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D0D8781-7DA5-4C6A-AEAF-D292788F201D</gtr:id><gtr:title>Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>gaBovGy2Zgx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A099FAA-E06F-45E7-9DA8-4B5BB1B5CB15</gtr:id><gtr:title>Rising ELISPOT count prior to the onset of symptoms of full-blown tuberculosis disease.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>dqeCZqJBHYo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93E9736-5939-4ED5-8EAE-6453E8843B2C</gtr:id><gtr:title>Evaluation of the contribution of major T cell subsets to IFN-gamma production in TB infection by ELISPOT.</gtr:title><gtr:parentPublicationTitle>Immunological investigations</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be0327eda774d7bba48096f2db083821"><gtr:id>be0327eda774d7bba48096f2db083821</gtr:id><gtr:otherNames>Lugos MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0882-0139</gtr:issn><gtr:outcomeId>DrPXrNn2XHM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFCF45F3-2265-40C8-A2CA-54CF57E819EC</gtr:id><gtr:title>Interferon-? ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_15390_20_23220919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ECA070F-C1CB-4D3A-84F7-CBF6512322F4</gtr:id><gtr:title>Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54e75f29ffc79c9257e04566c7c6017c"><gtr:id>54e75f29ffc79c9257e04566c7c6017c</gtr:id><gtr:otherNames>Adetifa IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>jkYgrivyfLp</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190081968</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>